Dyadic International Reports Q2 2026 Earnings with Mixed Financial Results
Dyadic International (DYAI) posted total revenue of $961,138 in the second quarter of 2026, flat compared to the prior year period. The company attributed this result to increased grant revenue from programs like CEPI and Gates Foundation, which offset a decline in research and development revenue. Despite these gains, Dyadic reported a net loss of $2.1 million or $0.06 per share for Q2 2026, up slightly compared to the previous year's loss. The company noted an operating loss increase by 18.8% due to higher costs and administrative expenses. Cash reserves stood at $4.8 million as of June 30, down from $8.6 million in December 2025. Management highlighted a significant productivity improvement—up 80% during pilot-scale runs—which is expected to reduce production costs by about 40%. Dyadic also reported six distinct recombinant protein product shipments post-quarter and secured grants totaling over $3.9 million from the Gates Foundation. Despite these developments, CFO Ping Rawson expressed concerns regarding the company's ability to continue as a going concern under accounting standards due to ongoing capital needs.
